Project Grant R01AI184703
- Federal Project Grant Award Summary Oregon State University received a $392,747 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 17, 2025, with a completion date of June 30, 2027. The grant supports biosynthetic and self-resistance investigations of kibdelomycin, a natural product antibiotic produced by Kibdelosporangium species and Amycolatopsis species with potential...
- Federal Project Grant Award Summary Oregon State University received a $408,375 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 14, 2025, with a completion date of June 30, 2027. The award supports research into phage-bacteria interactions and resistance mechanisms in Mycobacterium abscessus (MAB), an emerging pathogen associated with difficult-to-treat infections...
- Grant Award Summary Oregon Health & Science University (OHSU) received a $622,130 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective August 21, 2025, with a completion date of July 31, 2030. This research project, titled "Bacterial Manipulation of Atypical Ubiquitin Signaling," supports investigator-initiated biomedical research advancing scientific...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $1,174,636 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 1, 2025, through April 30, 2029. The grant supports research and development of next-generation endochin-like quinolone (ELQ) compounds for the treatment and prevention of malaria. The primary deliverable is the advancement...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $2,989,013 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded August 13, 2025, with completion targeted for July 31, 2029. The award supports research characterizing newly identified human cytomegalovirus (HCMV) entry receptors, with particular focus on epithelial and endothelial cells. The...
- Federal Grant Award Summary Oregon Health & Science University received a $482,625 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 1, 2026 through January 31, 2028. The award supports research and development services focused on developing long-acting antiretroviral therapy (LA-ART) for sustained Simian Immunodeficiency Virus (SIV) suppression in rhesus...
- Federal Project Grant Award Summary Princeton University received a $451,000 project grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 23, 2025, with completion scheduled for June 30, 2027. The grant funds research utilizing chemical synthetic lethality—a methodology whereby two individually benign molecules become lethal in combination—to identify novel antimicrobial targets and...
- Federal Grant Award Summary The University of Oregon received a $399,227 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective August 1, 2025, with completion targeted for May 31, 2030. This award supports fundamental research investigating the mechanisms of evolution at the host-pathogen interface, with particular focus on bacterial pathogens of humans. The research integrates...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $743,817 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 12, 2025, with a completion date of July 31, 2030. The grant funds research to identify and functionally characterize T cell receptor (TCR) families associated with protection from pulmonary tuberculosis (TB) infection and disease...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Ohio State University $222,098 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 3, 2025, for a project titled "Role of the Septin Cytoskeleton in Plasma Membrane Repair." The project, extending through January 31, 2027, focuses on fundamental research to elucidate the mechanisms by which septin cytoskeletal proteins facilitate plasma...
Oregon State University received a $495,688 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on February 2, 2026, with a completion date of January 31, 2031. The research initiative focuses on mechanistic and structural studies of ureido bond formation in the biosynthesis of three families of bioactive bacterial natural products: anabaenopeptins, syringolins, and muramycins. These naturally occurring compounds possess proteolytically stable ureido bonds that contribute significantly to their biological activity and potential therapeutic applications, including anti-cancer, anti-bacterial, and anti-viral properties. The research employs a multidisciplinary approach utilizing protein overexpression, isotope labeling, and related analytical methodologies to elucidate the biochemical mechanisms underlying ureido bond formation in non-ribosomal peptide synthetase (NRPS)-assembled intermediates. The project addresses a critical gap in understanding how these compounds are synthesized in microbial systems, with implications for manipulating biosynthetic pathways to produce novel natural products with enhanced or modified biological activities. This fundamental research supports the broader objective of developing new therapeutic candidates and advancing scientific knowledge of infectious disease mechanisms and potential treatments.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $495.7k | 2/2/26 |